Core Scientific (CORZ): Assessing Valuation After Securing $8.7B CoreWeave Deal and Pivot Toward Data Centers

If you’ve been watching Core Scientific (CORZ) lately, the company just gave investors a lot to think about. The latest catalyst is a major contract with CoreWeave, expected to generate up to $8.7 billion over the next 12 years. This deal could reshape the company’s growth narrative. Additionally, Core Scientific is shifting its core business, moving resources away from Bitcoin mining and accelerating its high-performance computing (HPC) infrastructure to meet the growing demand for data centers. For those considering their next move, these strategic shifts are making the stock difficult to overlook.

It’s not just about headlines; momentum in the share price has gathered steam, with a 42% jump over the past year and a 36% rally in the past three months alone. This kind of trend suggests investor enthusiasm is building, not fading. The company’s focus on HPC and its new multi-billion dollar contract are central, changing how investors are evaluating Core Scientific’s prospects as other business lines evolve.

But with shares on the move and future growth narratives now in play, investors are considering whether there is still potential upside or if the market has already priced in everything Core Scientific could deliver.

Most Popular Narrative: 15% Undervalued

According to the most widely followed narrative, Core Scientific is currently trading below its projected fair value, primarily due to anticipated growth from its HPC expansion and evolving contract pipeline.

The improved balance sheet following significant debt restructuring and raising $625 million through a convertible note offering at 0% interest rates positions the company to effectively fund future growth initiatives with lower interest costs, improving net margins. Strategic hires of data center professionals enhance execution capabilities, likely leading to increased operational efficiencies, positively impacting earnings as the company grows its data center business.

Want the inside story driving this bullish outlook? The narrative hinges on a bold transformation, with forecasts that could surprise even seasoned tech investors. What does analyst consensus really see as the drivers behind such a high price target? The answer is rooted in ambitious growth assumptions and a new business model pivot. These results could make or break the stock’s trajectory. Curious just how aggressive these projections are? The details tell the story.

Result: Fair Value of $19.05 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, uncertainties remain, including delays in HPC expansion and heavy reliance on a single major client. This reliance could quickly shift growth expectations.

Find out about the key risks to this Core Scientific narrative.

Another View: Industry Benchmarks Offer a Different Perspective

While analysts see Core Scientific as undervalued based on future earnings projections, a comparison of its price-to-sales ratio to the broader US Software industry suggests a higher valuation. Are future growth hopes already factored in?

See what the numbers say about this price — find out in our valuation breakdown.

Stay updated when valuation signals shift by adding Core Scientific to your watchlist or portfolio. Alternatively, explore our screener to discover other companies that fit your criteria.

Build Your Own Core Scientific Narrative

For those who want to dive deeper or prefer independent analysis, you can craft your own data-driven story for Core Scientific in just minutes. Do it your way.

A great starting point for your Core Scientific research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Ready for your next smart move? Don’t let other great opportunities pass you by. The right investment could be a click away. Use these handpicked searches to unlock new possibilities now:

• Tap into steady income streams and see which companies are offering dividend stocks with yields > 3% as part of their shareholder returns.
• Uncover innovators at the cutting edge by checking out stocks driving advancements in healthcare with the latest in healthcare AI stocks technology.
• Seize potential bargains others are missing by targeting stocks flagged as undervalued stocks based on cash flows for compelling value based on their future cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com